By demonstrating that miltefosine, a CCR5 agonist, promotes MK differentiation and platelet formation through activation of MAPK and JAK2/STAT signaling, we unveil a therapeutic axis for thrombocytopenia. This evidence concerns the gene JAK2 and Thrombocytopenia.